Coupling high-throughput genetics with phylogenetic information reveals an epistatic interaction on the influenza A virus M segment

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Wu, Nicholas C ^a,b,c   Du, Yushen ^a   Le, Shuai ^a,d   Young, Arthur P ^a   Zhang, Tian Hao ^a   Wang, Yuanyuan ^a   Zhou, Jian ^a   Yoshizawa, Janice M ^a   Dong, Ling ^a   Li, Xinmin ^a   Wu, Ting Ting ^a   Sun, Ren ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Coevolution analysis; Compensatory mutation; Fitness profiling; Mutagenesis; Natural sequence variation

Indexed keywords

ION CHANNEL; MATRIX PROTEIN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; COEVOLUTION; CONTROLLED STUDY; EPISTASIS; GENE STRUCTURE; GENETICS; HIGH THROUGHPUT GENETICS; HUMAN; HUMAN CELL; INFLUENZA A VIRUS; MATRIX SEGMENT; NUCLEIC ACID BASE SUBSTITUTION; PHYLOGENY; VIRUS GENE; VIRUS MORPHOLOGY; VIRUS STRAIN; GENE DELETION; HIGH THROUGHPUT SCREENING; PATHOGENICITY; PROCEDURES;

AMINO ACID SUBSTITUTION; EPISTASIS, GENETIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS; PHYLOGENY; SEQUENCE DELETION; VIRAL MATRIX PROTEINS;

EID: 84953897545     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-2358-7     Document Type: Article

References (72)

1. Sanjun R, Moya A, Elena SF. The contribution of epistasis to the architecture of fitness in an RNA virus. Proc Natl Acad Sci U S A. 2004; 101:15376-9.
2. Kryazhimskiy S, Dushoff J, Bazykin GA, Plotkin JB. Prevalence of epistasis in the evolution of influenza A surface proteins. PLoS Genet. 2011; 7:e1001301.
3. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, et al.Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999; 13:2349-59.
4. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet. 2009; 5:e1000578.
5. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010; 328:1272-5.
6. Gong LI, Bloom JD. Epistatically interacting substitutions are enriched during adaptive protein evolution. PLoS Genet. 2014; 10:e1004328.
7. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al.Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med. 2001; 193:375-86.
8. Sanjun R, Cuevas JM, Moya A, Elena SF. Epistasis and the adaptability of an RNA virus. Genetics. 2005; 170:1001-8.
9. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, et al.The influenza virus resource at the National Center for Biotechnology Information. J Virol. 2008; 82:596-601.
10. Kuiken C, Korber B, Shafer RW. HIV sequence databases. AIDS Rev. 2003; 5:52-61.
11. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics. 2005; 21:379-84.
12. Gong LI, Suchard MA, Bloom JD. Stability-mediated epistasis constrains the evolution of an influenza protein. Elife. 2013; e00631:2.
13. de Juan D, Pazos F, Valencia A. Emerging methods in protein co-evolution. Nat Rev Genet. 2013; 14:249-61.
14. Chen R, Holmes EC. Hitchhiking and the population genetic structure of avian influenza virus. J Mol Evol. 2010; 70:98-105.
15. Lang GI, Rice DP, Hickman MJ, Sodergren E, Weinstock GM, Botstein D, et al.Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations. Nature. 2013; 500:571-4.
16. Chao DL. Modeling the global transmission of antiviral-resistant influenza viruses. Influenza Other Respir Viruses. 2013; 7(Suppl 1):58-62.
17. Fowler DM, Fields S. Deep mutational scanning: a new style of protein science. Nat Methods. 2014; 11:801-7.
18. Qi H, Olson CA, Wu NC, Ke R, Loverdo C, Chu V, et al. A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog. 2014; 10:e1004064.
19. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, et al.High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution. Sci Rep. 2014; 4:4942.
20. Bloom JD. An experimentally determined evolutionary model dramatically improves phylogenetic fit. Mol Biol Evol. 2014; 31:1956-78.
21. Thyagarajan B, Bloom JD. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elife. 2014:e03300.
22. Al-Mawsawi LQ, Wu NC, Olson CA, Shi VC, Qi H, Zheng X, et al.High-throughput profiling of point mutations across the HIV-1 genome. Retrovirology. 2014; 11:124.
23. Wu NC, Olson CA, Du Y, Le S, Tran K, Remenyi R, et al. Functional Constraint Profiling of a Viral Protein Reveals Discordance of Evolutionary Conservation and Functionality. PLoS Genet. 2015; 11:e1005310.
24. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, et al.High-Throughput Identification of Loss-of-Function Mutations for Anti-Interferon Activity in the Influenza A Virus NS Segment. J Virol. 2014; 88:10157-64.
25. Lunzer M, Golding GB, Dean AM. Pervasive cryptic epistasis in molecular evolution. PLoS Genet. 2010; 6:e1001162.
26. Gómez-Puertas P, Albo C, Pérez-Pastrana E, Vivo A, Portela A. Influenza virus matrix protein is the major driving force in virus budding. J Virol. 2000; 74:11538-47.
27. Lohmeyer J, Talens LT, Klenk HD. Biosynthesis of the influenza virus envelope in abortive infection. J Gen Virol. 1979; 42:73-88.
28. Wharton SA, Belshe RB, Skehel JJ, Hay AJ. Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol. 1994; 75(Pt 4):945-8.
29. Roberts PC, Lamb RA, Compans RW. The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology. 1998; 240:127-37.
30. Moorthy NSHN, Poongavanam V, Pratheepa V. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery. Mini Rev Med Chem. 2014; 14:819-30.
31. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992; 176:119-30.
32. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis. 2011; 203:6-10.
33. Lee YT, Kim KH, Ko EJ, Lee YN, Kim MC, Kwon YM, et al.New vaccines against influenza virus. Clin Exp Vaccine Res. 2014; 3:12-28.
34. Terajima M, Cruz J, Leporati AM, Orphin L, Babon JAB, Co MDT, et al.Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. J Virol. 2008; 82:9283-7.
35. Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, et al.Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther. 2014; 22:233-8.
36. Taft AS, Ozawa M, Fitch A, Depasse JV, Halfmann PJ, Hill-Batorski L, et al.Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. Nat Commun. 2015; 6:7491.
37. Wu NC, Young AP, Dandekar S, Wijersuriya H, Al-Mawsawi LQ, Wu TT, et al.Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J Virol. 2013; 87:1193-9.
38. Li Z, Watanabe T, Hatta M, Watanabe S, Nanbo A, Ozawa M, et al.Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. J Virol. 2009; 83:4153-62.
39. Arzt S, Baudin F, Barge A, Timmins P, Burmeister WP, Ruigrok RW. Combined results from solution studies on intact influenza virus M1 protein and from a new crystal form of its N-terminal domain show that M1 is an elongated monomer. Virology. 2001; 279:439-46.
40. Nayak DP, Hui EKW, Barman S. Assembly and budding of influenza virus. Virus Res. 2004; 106:147-65.
41. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell. 1992; 69:517-28.
42. Pinto LH, Dieckmann GR, Gandhi CS, Papworth CG, Braman J, Shaughnessy MA, et al.A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc Natl Acad Sci U S A. 1997; 94:11301-6.
43. Wang C, Lamb RA, Pinto LH. Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. Biophys J. 1995; 69:1363-71.
44. Venkataraman P, Lamb RA, Pinto LH. Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus. J Biol Chem. 2005; 280:21463-72.
45. Okada A, Miura T, Takeuchi H. Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 ion channel from influenza a virus. Biochemistry. 2001; 40:6053-60.
46. Tang Y, Zaitseva F, Lamb RA, Pinto LH. The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue. J Biol Chem. 2002; 277:39880-86.
47. Squires RB, Noronha J, Hunt V, Garca-Sastre A, Macken C, Baumgarth N, et al.Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses. 2012; 6:404-16.
48. Elton D, Bruce EA, Bryant N, Wise HM, MacRae S, Rash A, et al.The genetics of virus particle shape in equine influenza A virus. Influenza Other Respir Viruses. 2013; 7(Suppl 4):81-9.
49. Grantham ML, Wu WH, Lalime EN, Lorenzo ME, Klein SL, Pekosz A. Palmitoylation of the influenza A virus M2 protein is not required for virus replication in vitro but contributes to virus virulence. J Virol. 2009; 83:8655-61.
50. Fares MA, McNally D. CAPS: coevolution analysis using protein sequences. Bioinformatics. 2006; 22:2821-22.
51. Fares MA, Travers SAA. A novel method for detecting intramolecular coevolution: adding a further dimension to selective constraints analyses. Genetics. 2006; 173:9-23.
52. Shishkov AV, Goldanskii VI, Baratova LA, Fedorova NV, Ksenofontov AL, Zhirnov OP, et al.The in situ spatial arrangement of the influenza A virus matrix protein M1 assessed by tritium bombardment. Proc Natl Acad Sci U S A. 1999; 96:7827-30.
53. Shishkov A, Bogacheva E, Fedorova N, Ksenofontov A, Badun G, Radyukhin V, et al.Spatial structure peculiarities of influenza A virus matrix M1 protein in an acidic solution that simulates the internal lysosomal medium. FEBS J. 2011; 278:4905-16.
54. Bialas KM, Desmet EA, Takimoto T. Specific residues in the 2009 H1N1 swine-origin influenza matrix protein influence virion morphology and efficiency of viral spread in vitro. PLoS One. 2012; e50595:7.
55. Govorkova EA, Gambaryan AS, Claas EC, Smirnov YA. Amino acid changes in the hemagglutinin and matrix proteins of influenza a (H2) viruses adapted to mice. Acta Virol. 2000; 44:241-8.
56. Xiang X. Functional studies of C-terminal domain of influenza A virus matrix 1(M1) protein in virus replication; 2011.
57. Olson CA, Wu NC, Sun R. A comprehensive biophysical description of pairwise epistasis throughout an entire protein domain. Curr Biol. 2014; 24:2643-51.
58. Doud MB, Ashenberg O, Bloom JD. Site-Specific Amino Acid Preferences Are Mostly Conserved in Two Closely Related Protein Homologs. Mol Biol Evol. 2015; 32:2944-60.
59. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, et al.Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997; 71:6662-70.
60. Özen A, Lin KH, Kurt Yilmaz N, Schiffer CA. Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. Proc Natl Acad Sci U S A. 2014; 111:15993-8.
61. Hakes L, Lovell SC, Oliver SG, Robertson DL. Specificity in protein interactions and its relationship with sequence diversity and coevolution. Proc Natl Acad Sci U S A. 2007; 104:7999-8004.
62. Wagner A. The origins of evolutionary innovations: a theory of transformative change in living systems; 2011.
63. Weinreich DM, Lan Y, Wylie CS, Heckendorn RB. Should evolutionary geneticists worry about higher-order epistasis?Curr Opin Genet Dev. 2013; 23:700-7.
64. Melamed D, Young DL, Miller CR, Fields S. Combining natural sequence variation with high throughput mutational data to reveal protein interaction sites. PLoS Genet. 2015; 11:e1004918.
65. Gulyás-Kovács A. Integrated analysis of residue coevolution and protein structure in ABC transporters. PLoS One. 2012; e36546:7.
66. Chakrabarti S, Panchenko AR. Structural and functional roles of coevolved sites in proteins. PLoS One. 2010; e8591:5.
67. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al.Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999; 96:9345-50.
68. Lou DI, Hussmann JA, McBee RM, Acevedo A, Andino R, Press WH, et al.High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc Natl Acad Sci U S A. 2013; 110:19872-7.
69. Hutchinson EC, Curran MD, Read EK, Gog JR, Digard P. Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus. J Virol. 2008; 82:11869-79.
70. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983; 22:2577-637.
71. Tien MZ, Meyer AG, Sydykova DK, Spielman SJ, Wilke CO. Maximum allowed solvent accessibilites of residues in proteins. PLoS One. 2013; e80635:8.
72. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature. 2008; 451:591-5.